Cargando…
SEOM clinical guideline for the management of cutaneous melanoma (2020)
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998/ https://www.ncbi.nlm.nih.gov/pubmed/33651321 http://dx.doi.org/10.1007/s12094-020-02539-9 |
_version_ | 1783680941343899648 |
---|---|
author | Majem, M. Manzano, J. L. Marquez-Rodas, I. Mujika, K. Muñoz-Couselo, E. Pérez-Ruiz, E. de la Cruz-Merino, L. Espinosa, E. Gonzalez-Cao, M. Berrocal, A. |
author_facet | Majem, M. Manzano, J. L. Marquez-Rodas, I. Mujika, K. Muñoz-Couselo, E. Pérez-Ruiz, E. de la Cruz-Merino, L. Espinosa, E. Gonzalez-Cao, M. Berrocal, A. |
author_sort | Majem, M. |
collection | PubMed |
description | Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. |
format | Online Article Text |
id | pubmed-8057998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-80579982021-05-05 SEOM clinical guideline for the management of cutaneous melanoma (2020) Majem, M. Manzano, J. L. Marquez-Rodas, I. Mujika, K. Muñoz-Couselo, E. Pérez-Ruiz, E. de la Cruz-Merino, L. Espinosa, E. Gonzalez-Cao, M. Berrocal, A. Clin Transl Oncol Clinical Guides in Oncology Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. Springer International Publishing 2021-03-02 2021 /pmc/articles/PMC8057998/ /pubmed/33651321 http://dx.doi.org/10.1007/s12094-020-02539-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Guides in Oncology Majem, M. Manzano, J. L. Marquez-Rodas, I. Mujika, K. Muñoz-Couselo, E. Pérez-Ruiz, E. de la Cruz-Merino, L. Espinosa, E. Gonzalez-Cao, M. Berrocal, A. SEOM clinical guideline for the management of cutaneous melanoma (2020) |
title | SEOM clinical guideline for the management of cutaneous melanoma (2020) |
title_full | SEOM clinical guideline for the management of cutaneous melanoma (2020) |
title_fullStr | SEOM clinical guideline for the management of cutaneous melanoma (2020) |
title_full_unstemmed | SEOM clinical guideline for the management of cutaneous melanoma (2020) |
title_short | SEOM clinical guideline for the management of cutaneous melanoma (2020) |
title_sort | seom clinical guideline for the management of cutaneous melanoma (2020) |
topic | Clinical Guides in Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998/ https://www.ncbi.nlm.nih.gov/pubmed/33651321 http://dx.doi.org/10.1007/s12094-020-02539-9 |
work_keys_str_mv | AT majemm seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT manzanojl seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT marquezrodasi seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT mujikak seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT munozcouseloe seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT perezruize seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT delacruzmerinol seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT espinosae seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT gonzalezcaom seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 AT berrocala seomclinicalguidelineforthemanagementofcutaneousmelanoma2020 |